BioWorld28d
Discovery of microtubule polymerization inhibitor with excellent anticancer activity
Southern Medical University scientists have reported the discovery and preclinical characterization of novel microtubule-inhibiting agents being developed for the treatment of cancer. Discovery of ...
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...
pharmaphorum8mon
FDA OKs wider use of Almirall’s actinic keratosis drug
First approved in 2020, first-in-class microtubule inhibitor Klisyri (tirbanibulin 1%) reached the market in early 2021, joining a short list of therapies in the US that are available for AK ...
Nature4y
Regenacy is poised to deliver the first treatment for peripheral neuropathy
The company’s lead compound ricolinostat is an oral, selective inhibitor of the microtubule-modifying enzyme histone deacetylase 6 (HDAC6). With first-in-class potential, ricolinostat is ...
Nature5y
Developing isogenic cell models with CRISPR: an EML4-ALK fusion NSCLC cell line
An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated ... oncogene and tested for its sensitivity to inhibitors of ALK. We employed the CRISPR ...